Increased MCL1 dependency leads to new applications of BH3-mimetics in drug-resistant neuroblastoma.

Maureen JacobSara WiedemannDaniela BrücherNadja M PieperMoni BirkholdVinzenz SärchenJan JerochMelanie C DemesSteffen GretserYannick BraunElise GradhandFlorian RothweilerMartin MichaelisJindrich CinatlMeike Vogler

Published in: British journal of cancer (2023)

These data highlight that the application of BH3-mimetics may differ between first line treatment and relapsed disease. Combination of NK cell-based immunotherapy with BH3-mimetics may further increase killing of chemoresistant neuroblastoma, outlining a new treatment strategy for relapsed neuroblastoma.

Keyphrases

drug resistant
acute lymphoblastic leukemia
multidrug resistant
nk cells
acute myeloid leukemia
acinetobacter baumannii
multiple myeloma
diffuse large b cell lymphoma
hodgkin lymphoma
electronic health record
pseudomonas aeruginosa
deep learning
artificial intelligence